预约演示

更新于：2026-02-24

Cabozantinib (s)-Malate

苹果酸卡博替尼

更新于：2026-02-24

概要

基本信息

药物类型

小分子化药

别名

cabozantinib、Cabozantinib Malate、Cabozantinib s-malate (USAN)

+ [10]

靶点

AXL x RET x ROS1 x TYRO3 x Tie-2 x TrkB x VEGFR1 x VEGFR2 x VEGFR3 x c-Kit x c-Met

作用方式

抑制剂、拮抗剂

作用机制

AXL抑制剂(AXL受体酪氨酸激酶抑制剂)、RET抑制剂(酪氨酸蛋白激酶受体RET抑制剂)、ROS1抑制剂(原癌基因酪氨酸蛋白激酶ROS抑制剂)

治疗领域

肿瘤消化系统疾病内分泌与代谢疾病+ [11]

在研适应症

神经内分泌肿瘤高分化胰腺内分泌肿瘤胰腺外神经内分泌肿瘤+ [193]

非在研适应症

晚期胆管癌晚期乳腺癌甲状腺未分化癌+ [42]

原研机构

Exelixis, Inc.

在研机构

National Cancer Institute

Exelixis, Inc.

Bristol Myers Squibb Co.

+ [20]

非在研机构

University of Washington

江苏豪森药业集团有限公司

EMD Serono, Inc.

权益机构

Ipsen SA

Takeda Pharmaceutical Co., Ltd.

Chugai Pharmaceutical Co., Ltd.

+ [7]

最高研发阶段批准上市

首次获批日期

美国 (2012-11-29),

甲状腺髓样癌

最高研发阶段(中国)临床3期

特殊审评快速通道 (美国)、孤儿药 (美国)、优先审评 (美国)、突破性疗法 (美国)

登录后查看时间轴

结构/序列

分子式C32H30FN3O10

InChIKeyHFCFMRYTXDINDK-WNQIDUERSA-N

CAS号1140909-48-3

关联

282

项与苹果酸卡博替尼相关的临床试验

NCT06900595

/ Recruiting临床2期IIT

A Phase II Study of Cabozantinib in Combination With Cemiplimab (Cabo-Cemiplimab) Versus Cabozantinib Alone in Adolescents and Adults With Advanced Adrenocortical Cancer

This phase II trial compares the effect of giving cabozantinib with or without cemiplimab in patients with adrenocortical cancer that has spread to nearby tissue or lymph nodes (locally advanced), and that cannot be removed by surgery (unresectable) or that has come back after a period of improvement (recurrent) or that has spread from where it first started (primary site) to other places in the body (metastatic). Cabozantinib is in a class of medications called tyrosine kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply, which may help keep cancer cells from growing. Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib with cemiplimab may kill more tumor cells in patients with locally advanced unresectable or recurrent/metastatic adrenocortical cancer.

开始日期2026-07-19

申办/合作机构

National Cancer Institute

NCT07383441

/ Not yet recruiting临床3期IIT

Phase III Double Blinded Trial of Immune-Based Therapy With a Live Biotherapeutic MO-03 or Placebo for Frontline Therapy of Advanced Clear Cell Renal Cell Carcinoma [BioFront Trial]

This phase III trial compares the effect of adding live biotherapy, MO-03, to standard of care (SOC) immunotherapy, including ipilimumab, nivolumab, axitinib, pembrolizumab, cabozantinib, and lenvatinib, to SOC immunotherapy alone in treating patients with clear cell renal cell cancer that may have spread from where it first started (primary site) to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started to other places in the body (metastatic). Studies have shown that gut health (the gut microbiome) may impact the effectiveness of immunotherapy. The microbiome includes all of the bacteria and organisms naturally found in the digestive tract. MO-03, a type of biotherapy, contains material from living organisms that may help keep the digestive tract healthy and may help to increase the effect of immunotherapy. Immunotherapy with monoclonal antibodies, such as ipilimumab, nivolumab, pembrolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Axitinib, cabozantinib, and lenvatinib are a type of angiogenesis inhibitor and tyrosine kinase inhibitor (TKI) that block certain proteins which may help keep tumor cells from growing and may also help prevent the growth of new blood vessels that tumors need to grow. Adding MO-03 to SOC immunotherapy may be more effective than SOC immunotherapy alone in treating patients with advanced or metastatic clear cell renal cell cancer.

开始日期2026-06-10

申办/合作机构

SWOG

[+1]

NCT07187869

/ Not yet recruiting临床1期IIT

Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study

The goal of our study is to explore how treatments affect the bone immune microenvironment and determine the best treatment options for patients with metastatic kidney cancer to the bone. This could prevent skeletal complications and improve patient outcomes.

开始日期2026-03-31

申办/合作机构

The University of Texas MD Anderson Cancer Center

[+1]

100 项与苹果酸卡博替尼相关的临床结果

登录后查看更多信息

100 项与苹果酸卡博替尼相关的转化医学

登录后查看更多信息

100 项与苹果酸卡博替尼相关的专利（医药）

登录后查看更多信息

2,062

项与苹果酸卡博替尼相关的文献（医药）

2026-03-01·DRUG RESISTANCE UPDATES

UBL3 governs VEGFR inhibitor resistance by activating NOTCH signaling in renal cell carcinoma

Article

作者: Zhang, Xiaoping ; Fang, Kanglin ; Shi, Jian ; Yang, Hongmei ; Miao, Daojia ; Gong, Jinshuo ; Tan, Diaoyi ; Xiong, Zhiyong ; Wu, Songming ; Zhao, Chuanyi ; Yang, Junkai ; Ruan, Hailong ; Xiao, Wen ; Ye, Yuzhong ; Lv, Qingyang ; Lu, Feiyi

BACKGROUND:

Targeted therapy is the first-line treatment for patients with metastatic renal cell carcinoma (RCC), with vascular endothelial growth factor receptor inhibitors (VEGFRis) constituting the bulk of regimens used. Although the repertoire of VEGFRis for RCC now spans from sunitinib to cabozantinib, resistance to treatments has emerged as a common and prominent challenge. Thus, identifying novel therapeutic targets has become essential for enhancing the antitumor efficacy of current treatments and inhibiting RCC progression.

METHOD:

To investigate the potential mechanisms underlying VEGFRi resistance in RCC, we performed a genome-wide CRISPR/Cas9 library screen under sunitinib and cabozantinib treatment and identified UBL3 as a key driver of VEGFRi resistance in RCC cells. The critical role of UBL3 in promoting VEGFRi resistance was validated using CCK8 assays, flow cytometry, TUNEL assays, and bioinformatics analyses. To elucidate the molecular mechanisms underlying UBL3, we utilized western blotting, RNA sequencing, chromatin immunoprecipitation, small extracellular vesicles (sEVs) isolation, and Astral-DIA proteomics. The contribution of UBL3 to VEGFRi resistance was further confirmed through comprehensive in vitro and in vivo experiments.

RESULTS:

UBL3 was confirmed to suppress apoptosis and promote VEGFRi resistance through NOTCH signaling activation. Further investigations highlighted the importance of NOTCH signaling in VEGFRi resistance in RCC via the NOTCH-PTEN-AKT and NOTCH-FOS pathways and revealed the mechanisms by which UBL3 activated NOTCH signaling. On the one hand, UBL3 formed complex with NOTCH2 and ADAM17 simultaneously, accelerating ADAM17-mediated cleavage of NOTCH2. On the other hand, UBL3-modified NOTCH2 was sorted into sEVs, which were taken up by recipient cells, activating NOTCH signaling and thereby transmitting VEGFRi resistance. Finally, lipid nanoparticle-mediated delivery of the CRISPR/Cas9 knockout system targeting UBL3 effectively restored the sensitivity of RCC tumors to VEGFRis.

CONCLUSION:

This study emphasized the importance of UBL3 in VEGFRi resistance in RCC and proposed that UBL3 activated NOTCH signaling through two distinct pathways, thereby suppressing cancer apoptosis and promoting resistance to VEGFRis. These findings provided a solid scientific foundation and paved the way for the development of novel therapeutic strategies for patients with advanced RCC.

2026-03-01·LIFE SCIENCES

Cabozantinib induces NLRP3-CASP1-GSDMD-dependent pyroptosis in hepatocellular carcinoma

Article

作者: Ou, Da-Liang ; Chang, Hsin-Yi ; Feng, Zhi-Rui ; Hsu, Chiun ; Chung, Chih-Hung ; Lin, Li ; Yang, Muh-Hwa ; Cheng, Ann-Lii ; Cheng, Han-Ying ; Jian, Cheng-Zhe ; Hsu, Chia-Lang

AIMS:

Cabozantinib is a multi-target tyrosine kinase inhibitor approved for second-line treatment of advanced hepatocellular carcinoma (HCC). While its antiangiogenic and antiproliferative effects are well known, its immunomodulatory mechanisms remain incompletely understood. Here, we aimed to investigate the novel immunomodulatory mechanism of cabozantinib, focusing on its role in inducing pyroptotic cell death in HCC cells and myeloid-derived suppressor cells (MDSCs).

MATERIALS AND METHODS:

Cabozantinib-induced pyroptosis was evaluated in HCC cell lines and MDSCs. The involvement of the canonical NLRP3-CASP1-GSDMD pathway was validated using MDSCs induced from Nlrp3 knockout mice and Gsdmd knockout HCC cells. In vivo efficacy and immunomodulation were assessed using Gsdmd knockout Hepa1-6 tumors in immunocompetent mice, analyzed via flow cytometry, single-cell RNA sequencing, and phosphoproteomics.

KEY FINDINGS:

We show that cabozantinib induces pyroptotic cell death in both HCC cells and MDSCs via the canonical NLRP3-CASP1-GSDMD pathway. Disruption of this pathway using MDSCs induced from Nlrp3 knockout mice or Gsdmd knockout HCC cells abrogated cabozantinib-induced pyroptosis. Critically, implantation of Gsdmd knockout tumors in vivo abolished the antitumor and immunomodulatory effects of cabozantinib, confirming the necessity of GSDMD-mediated pyroptosis. Furthermore, cabozantinib reduced MDSC accumulation and enhanced cytotoxic CD8⁺ T cell responses, findings further supported by phosphoproteomic analysis showing pyroptosis-associated signaling alterations.

SIGNIFICANCE:

These findings reveal a mechanistic link between cabozantinib-induced pyroptosis and immune activation. Our results provide a strong rationale for the clinical combination of cabozantinib with immunotherapy in the treatment of HCC.

2026-03-01·Clinical Genitourinary Cancer

Clinical Outcomes of Targeted Therapies Following HIF-2α Inhibition in Metastatic Renal Cell Carcinoma: A Real-World Analysis

Article

作者: Esteban-Villarrubia, Jorge ; Flippot, Ronan ; de Velasco, Guillermo ; Sparagna, Ileana ; Manneh, Ray ; Iacovelli, Roberto ; Schütz, Fábio ; Plata, David ; Rioja, Patricia ; Rey-Cárdenas, Macarena

INTRODUCTION:

Belzutifan, a HIF-2α inhibitor, represents a new therapeutic option for patients with advanced clear-cell renal cell carcinoma (ccRCC); however, data regarding optimal postprogression treatment strategies is limited. With an expanding role of HIF-2α inhibitors, this study aimed to assess the activity of targeted therapies (TT) following belzutifan failure.

METHODS:

We conducted a multicenter retrospective study including patients with ccRCC treated with belzutifan-based regimens who subsequently received further TT. The primary endpoint were time to treatment failure (TTF) and objective response rate (ORR). Secondary endpoints were progression-free survival (PFS), and overall survival (OS).

RESULTS:

Thirty-five patients were included. Most (79%) received vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) after belzutifan, primarily in the third-line setting or beyond. The most frequently used agents were cabozantinib (46%), axitinib (29%), and everolimus (14%), the latter representing a mechanistically distinct agent as a mammalian target of rapamycin (mTOR) inhibitor. The median TTF for subsequent TT was 6.13 months (mo) (95% CI, 3.44-11.28). ORR was 20% and a median PFS was 6.13 mo (95% CI, 5.02-12.2). The median OS was 11.28 mo (95% CI, 6.89-NR), with a 1-year survival rate of 49% (95% CI = 31-65).

CONCLUSIONS:

Despite extensive prior treatment, patients experienced clinical benefit from TT, particularly VEGFR-TKIs, after progression on belzutifan. These findings support the feasibility of sequencing TT following belzutifan-based regimens in advanced ccRCC, and highlight the need to further define optimal therapeutic sequencing strategies.

874

项与苹果酸卡博替尼相关的新闻（医药）

14 小时之前

·研发客

益普生公布2025年业绩

在肿瘤（4.1%[1]）、罕见病（102.5%[1]）和神经科学（9.7%[1]）三个治疗领域增长的推动下，以固定汇率计算，2025财年总销售额增长10.9%[1]，以报告汇率计算增长8.1%；索马杜林®销售额增长4.3%[1]，除索马杜林外其他产品实现了销售额双位数增长（14.2%[1]） 2025财年核心营业利润为12.94亿欧元，以报告汇率计算增长16.7%，核心营业利润率占总销售额的35.2%，增长2.6个点 2025年研发管线持续推进，包括重大监管和临床里程碑的推动，整合多项具有全球权益和创新模式的临床前资产，以及收购ImCheck Therapeutics获得中期候选药物 2026年有望实现五项重大监管和临床里程碑，并将公布IPN10200在医美适应症中的完整数据结果公布2026年全年财务指引[2]，以固定汇率计算，总销售额增长超过13.0%[3]，核心营业利润率超过总销售额的35.0%，基于除索马杜林外产品组合实现加速增长，同时由于兰瑞肽仿制药生产方面的挑战导致索马杜林销售额增长的假设。巴黎2026年2月13日-- 全球特药领域生物制药公司益普生（Euronext: IPN; ADR: IPSEY）今日公布了2025全年（财年）和2025年第四季度的财务业绩。益普生首席执行官David Loew表示："益普生在2025年实现了强劲的销售额和利润增长。我们在三个治疗领域继续深耕，其中Iqirvo的表现尤为突出。我们推进了多个研发管线项目，并通过有针对性的业务开发，包括收购ImCheck Therapeutics，进一步加强了创新引擎。我们还在同类首创差异化长效重组分子IPN10200中取得了充满希望的概念验证结果。 2026年，我们有望再次实现销售额的双位数增长，这将得益于整个产品组合的增长提速，以及在兰瑞肽仿制药生产受限的背景下，索马杜林的市场前景进一步改善。我们预计今年将实现五项监管和临床里程碑，并进一步落实我们的外部创新战略。" 2026年全年指引及中期展望益普生为2026财年制定了以下财务指引：以固定汇率计算，总销售额增长超过13.0%。基于2026年1月的平均汇率水平，预计汇率将对总销售额产生约2%的不利影响。核心营业利润率超过总销售额的35.0%，其中已计入因预期的早期和中期外部创新机会所产生的额外研发费用。总销售额和核心营业利润率指引基于如下假设：除索马杜林外的产品组合销售额加速增长，以及因兰瑞肽仿制药生产受限带来的索马杜林销售额增长。该指引排除了潜在的后期（Ⅲ期临床开发或之后）业务开发交易的任何影响。基于对长期假设（包括竞争强度和产品生命周期考量）的持续评估，益普生已不再将Onivyde和达唯珂实现5亿欧元销售峰值作为目标。基于索马杜林因兰瑞肽仿制药持续生产受限所带来的更高销售预期，以及更广泛产品组合的业绩表现，益普生对2027年中期目标充满信心，认为2023~2027年间实现总销售额年均增长率[5]至少7%，并在2027年实现核心营业利润率至少占总销售额的32%[6]。研发管线进展 2025年，益普生在不同产品组合实现多项重要的监管和临床里程碑，反映了三个治疗领域的研发管线持续推进。 2025年第一季度，欧洲药品管理局（EMA）受理了用于治疗儿童低分化胶质瘤的口服Ⅱ型RAF-激酶抑制剂tovorafenib的监管申报文件。 2025年5月，益普生在欧洲肝脏研究学会（EASL）大会上公布了Iqirvo®（elafibranor）ELMWOOD研究的Ⅱ期数据，证明了在原发性硬化性胆管炎患者的12周治疗中具有良好安全性特征和剂量依赖性疗效。原发性硬化性胆管炎是一种医疗需求高度未满足的疾病。 2025年7月，基于Ⅲ期CABINET试验的积极结果，欧盟委员会批准Cabometyx®（cabozantinib）用于治疗有既往治疗史的晚期神经内分泌肿瘤（NETs）。 2025年9月，益普生公布了IPN10200在医美领域LANTIC Ⅱ期临床的积极数据，显示该产品具有差异化的长效临床特征。年内，益普生还启动了IPN10200用于颈部张力障碍的Ⅱ期研究，这是该长效重组分子跨治疗和医美适应症的全球开发计划中的第四项临床研究。 2025年12月，益普生宣布，关于将fidrisertib用于进行性骨化性纤维发育不良（FOP）的关键性Ⅱ期FALKON试验未达到主要终点，研究随后终止；fidrisertib总体耐受性良好，未发现安全性问题。此外，益普生启动了多项肿瘤I期临床研究，包括RAF抑制剂IPN01195、抗体偶联药物IPN60300和T细胞激活剂IPN01203，进一步强化了益普生的肿瘤靶向药物研发管线。外部创新 2025年12月，益普生通过收购ImCheck Therapeutics进一步扩展了肿瘤免疫治疗产品组合。ImCheck Therapeutics是一家致力于开发下一代肿瘤免疫疗法的生物技术公司，产品包括IPN60340（ICT01），这是一种靶向BTN3A的同类首创单克隆抗体，目前处于Ⅰ/Ⅱ期开发阶段，计划于2026年启动Ⅱb/Ⅲ期研究。IPN60340有望在一线不适合强化治疗的急性髓系白血病（一种常见于老年人的侵袭性血癌）患者中，通过联合用药方案，形成新的治疗标准。在2025年美国临床肿瘤学会年度会议上口头报告的Ⅰ/Ⅱ期EVICTION试验的期中数据显示，ICT01联合维奈克拉和阿扎胞苷（Ven - Aza）治疗获得了令人鼓舞的高缓解率。在这项单臂试验中，与历史标准治疗数据相比，新诊断患者的所有分子亚型（包括对标准治疗[Ven-Aza]反应较差的亚型）的治疗缓解率几乎提高了一倍。2026年1月，益普生还宣布美国FDA已授予IPN60340突破性疗法认定，用于一线不适合强化治疗的急性髓系白血病。 2025年12月，益普生通过另外两项有针对性的业务开发和研究合作，进一步加强了肿瘤学和早期研发管线。益普生与先声再明（Simcere Zaiming）签署独家授权协议，获得SIM0613，一款靶向LRRC15的抗体偶联药物，在大中华区以外地区的权益。益普生还宣布与蒙特利尔大学和IRICoR达成一项新的研究合作和选择权协议，该协议涵盖两个处于发现阶段的研究项目，重点关注对MAP激酶通路具有互补作用的新型抑制途径。 2026年即将达到的里程碑益普生预计2026年产品组合将迎来多项关键里程碑，包括： Tovorafenib（FIREFLY-1）-针对儿童低分化胶质瘤的欧洲监管决策蓓尔唯（BOLD）- 胆管闭锁关键性Ⅲ期试验的数据读出 Iqirvo（ELSPIRE）- 原发性胆汁性胆管炎关键性Ⅲ期试验的数据读出吉适（BEOND）- 慢性和发作性偏头痛关键性Ⅲ期试验的数据读出 IPN10200（LANTIC）- 外眦纹和抬头纹Ⅱ期试验的数据读出这些里程碑进一步加强了益普生致力于推进创新疗法，为全球患者扩大治疗选择的承诺。 IPN10200的Ⅱ期LANTIC研究的完整数据预计将于2026年上半年在即将召开的大会上公布，研究结果此前已显示出积极的同类首创、差异化长效临床特征，并支持启动Ⅲ期研究。 Galderma仲裁事项 2026年1月，国际商会（ICC）仲裁庭已作出有利于益普生的最终裁决，驳回了Galderma就益普生终止研发协议提起的仲裁请求。仲裁庭确认了益普生对在美学领域的临床阶段毒素项目的全部权利，包括IPN10200。益普生将继续评估所有方案，以最大限度地发挥长效方案的价值。环境、社会和治理 2025年，益普生在推进宏伟的可持续发展战略方面采取了重要措施，持续将可持续发展融入公司运营和决策中。从减少环境足迹到提高患者可及性，再到发扬企业文化，益普生进一步加强对造福患者、员工、社区和地球的承诺。益普生在多个环境目标方面取得了良好进展，包括：范围1和范围2的温室气体排放量减少54%（与2019年基线相比）范围3的排放量减少16%，完全符合我们的2030年目标（与2019年基线相比）益普生全球用电现在100%来自可再生能源在"未来车队"项目的影响下，截至2025年，公司车队中电动汽车占比已达55%。益普生因在环境行动和透明度方面的最佳实践，以及对环境依赖性、风险和机遇的全面理解，成功斩获CDP A级评级。益普生很自豪地成为首批在执行领导团队内实现完全性别均等的生物制药公司之一，目前全球领导团队中女性占比达53%。说明除非另有说明，否则本报告中所有财务数据均以百万欧元（€m）为单位。除非另有说明，本报告的业绩涵盖2025年12月31日之前的12个月（2025财年）和2025年12月31日之前的3个月（2025年第四季度），而数据对比的对象为2024年12月31日之前的12个月（2024财年）和2024年12月31日之前的3个月（2024年第四季度）。除非另有说明，否则评论基于2025财年的业绩。关于益普生益普生是一家全球性的生物制药公司，专注于在肿瘤学、罕见病和神经科学三个治疗领域为患者提供革新型药物。我们的研发管线由内部和外部创新推动，并由近100年的开发经验以及位于美国、法国和英国的全球中心提供支持。我们的团队遍布全球40多个国家，在世界各地均有合作伙伴，这使我们能够为100多个国家的患者提供药物。益普生在巴黎（泛欧交易所：IPN）上市并通过赞助的I级美国存托凭证项目（ADR：IPSEY）在美国上市交易。更多信息，请访问ipsen.com。关于益普生中国益普生集团于1992年进入中国，于2021年在上海成立中国区总部，并于2022年根据集团业务变动，同步剥离多元健康业务，专注于特药领域，针对三大疾病领域（肿瘤、罕见病、神经科学），益普生中国将持续推出创新治疗方案以满足中国患者亟待解决的治疗需求。 [1] 以固定汇率（CER）计算，即通过应用前一时期使用的汇率重新计算相关时期的业绩，排除任何外汇影响。 [2] 排除潜在后期（Ⅲ期临床开发或后续开发）外部创新交易的任何影响。 [3] 基于2026年1月的平均汇率水平，预计货币汇率将对总销售额产生约2%的不利影响。 [4] 合并业绩摘录。公司审计师对合并财务报表进行了审查。 [5] 以固定汇率计算的2023~2027复合年均增长率（CAGR） [6] 排除潜在后期（Ⅲ期临床开发或后续开发）外部创新交易的任何影响。

临床3期并购财报申请上市

2026-02-22

·道道之道

【本周医刊】2026年第8周医学期刊更新

2026年第8周（2026.02.15-2026.02.21）重要医学期刊论著更新如下： 1.综合期刊 LANCET 题目：Tenecteplase versus standard medical treatment for basilar artery occlusion within 24 h (TRACE-5): a multicentre, prospective, randomised, open-label, blinded-endpoint, superiority, phase 3 trial 翻译：替奈普酶对比标准药物治疗 24 小时内基底动脉闭塞（TRACE‑5）：一项多中心、前瞻性、随机、开放标签、终点盲法、优效性Ⅲ期临床试验题目：Recombinant factor VIIa versus placebo for spontaneous intracerebral haemorrhage within 2 h of symptom onset (FASTEST): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial 翻译：重组凝血因子Ⅶa对比安慰剂用于症状发作2 小时内自发性脑出血（FASTEST）：一项多中心、双盲、随机、安慰剂对照Ⅲ期临床试验题目：Cumulative incidence of advanced breast cancer in women aged 40–49 years in the Japan Strategic Anti-cancer Randomised Trial (J-START) of adjunctive ultrasonography: a prespecified secondary analysis 翻译：日本附加超声筛查抗癌随机试验（J‑START）中40～49岁女性晚期乳腺癌累积发病率：一项预设亚组分析题目：Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial 翻译：艾菲莫肽 α（BOS‑580）每月一次治疗F2/F3 纤维化代谢相关脂肪性肝炎：一项24 周、随机、双盲、安慰剂对照Ⅱ期临床试验结果 NEW ENGLAND JOURNAL OF MEDICINE 题目：Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma 翻译：泰莱斯塔单抗联合达雷妥尤单抗治疗复发或难治性多发性骨髓瘤题目：Hematopoietic Stem-Cell Gene Therapy for Cystinosis 翻译：胱氨酸病的造血干细胞基因治疗题目：An Antibody–Oligonucleotide Conjugate for Myotonic Dystrophy Type 1 翻译：用于 1 型强直性肌营养不良的抗体- 寡核苷酸偶联物题目：Transcatheter or Surgical Aortic-Valve Replacement in Low-Risk Patients at 7 Years 翻译：低危患者经导管或外科主动脉瓣置换术后7 年结局 JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 题目：Expectant Management vs Medication for Patent Ductus Arteriosus in Preterm Infants: The PDA Randomized Clinical Trial 翻译：期待治疗对比药物治疗早产儿动脉导管未闭：PDA随机临床试验题目：Cryopreserved vs Liquid-Stored Platelets for the Treatment of Surgical Bleeding: The CLIP-II Randomized Noninferiority Clinical Trial 翻译：冻存血小板对比液态保存血小板治疗外科出血：CLIP‑II随机非劣效性临床试验题目：Prenatal Exposure to Acid-Suppressive Medications and Risk of Neuropsychiatric Disorders in Children 翻译：产前暴露于抑酸药物与儿童神经精神疾病发病风险的关系 NATURE MEDICINE 题目：Colonoscopy and fecal immunochemical testing versus usual care in diagnostic colorectal cancer screening: the SCREESCO randomized controlled trial 翻译：结肠镜联合粪便免疫化学检测对比常规方案用于结直肠癌诊断性筛查：SCREESCO随机对照试验题目：Predicting onset of symptomatic Alzheimerʼs disease with plasma p-tau217 clocks 翻译：血浆 p-tau217 时钟预测症状性阿尔茨海默病发病题目：Bispecific T cell engagers for treatment-refractory autoimmune connective tissue diseases 翻译：双特异性 T 细胞衔接器用于治疗难治性自身免疫性结缔组织病题目：Deciphering the etiology of the 2024 outbreak of undiagnosed febrile illness in Panzi, Democratic Republic of the Congo 翻译：解析刚果民主共和国潘齐市 2024 年不明原因发热疫情的病因题目：Effects of a comprehensive antibiotic stewardship program on antibiotic prescribing for acute respiratory infections in rural facilities: a cluster randomized trial 翻译：综合性抗生素管理项目对基层医疗机构急性呼吸道感染抗生素处方的影响：一项整群随机试验题目：A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial 翻译：短效致幻剂干预治疗重度抑郁症：一项Ⅱa期随机安慰剂对照试验题目：A quantitative DOPA decarboxylase biomarker for diagnosis in Lewy body disorders 翻译：用于路易体病诊断的定量多巴脱羧酶生物标志物 BMJ-BRITISH MEDICAL JOURNAL 题目：Menopausal hormone therapy and long term mortality 翻译：绝经激素治疗与长期死亡率题目：Vitamin D supplementation before in vitro fertilisation in women with polycystic ovary syndrome 翻译：多囊卵巢综合征女性体外受精前的维生素D 补充 INNOVATION（本周无更新） LANCET DIGITAL HEALTH（本周无更新） NPJ DIGITAL MEDICINE 题目：A large-scale benchmark for evaluating large language models on medical question answering in Romanian 翻译：面向罗马尼亚语医学问答的大语言模型大规模基准评测题目：Artificial intelligence–enhanced microsurgical training: a systematic review 翻译：人工智能增强的显微外科培训：一项系统评价题目：Defining operational safety in clinical artificial intelligence systems 翻译：临床人工智能系统中操作性安全性的定义题目：CancerLLM: a large language model in cancer domain 翻译：CancerLLM：一款肿瘤领域专用大语言模型题目：Robust and interpretable unit level causal inference in neural networks for pediatric myopia 翻译：基于神经网络的儿童近视个体水平稳健可解释因果推断题目：Large language models in systematic review and meta-analysis of surgical treatments for vaginal vault prolapse 翻译：大语言模型在阴道穹隆脱垂手术治疗系统评价与Meta 分析中的应用题目：Hierarchical deep learning pipeline for robust cervical parameter measurement in radiographs with C7 obscuration 翻译：针对 C7 节段遮挡X 光片的稳健性颈椎参数测量分层深度学习流程题目：Benchmarking large language model-based agent systems for clinical decision tasks 翻译：面向临床决策任务的大语言模型智能体系统基准测试题目：Computer vision applications in vascular surgery: a systematic review and critical appraisal 翻译：计算机视觉在血管外科中的应用：一项系统评价与批判性评价题目：Empowering genetic discoveries and cardiovascular risk assessment by predicting electrocardiograms from genotype 翻译：通过基因型预测心电图以助力遗传学发现与心血管风险评估题目：BRIDGE pilot study: a bilateral regulatory investigation of data governance and exchange 翻译：BRIDGE 试点研究：一项关于数据治理与数据交换的双边监管调查题目：Artificial intelligence-based incident analysis and learning system to enhance patient safety and improve treatment quality 翻译：基于人工智能的不良事件分析与学习系统：提升患者安全与治疗质量题目：Health economic simulation modeling of an AI-enabled clinical decision support system for coronary revascularization 翻译：面向冠脉血运重建的人工智能临床决策支持系统卫生经济学模拟建模题目：A deep learning model integrating structured data and clinical text for predicting atrial fibrillation recurrence 翻译：整合结构化数据与临床文本的深度学习模型预测心房颤动复发题目：Risk Prediction of Chronic Kidney Disease Progression in Type 2 Diabetes Mellitus Across Diverse Populations 翻译：不同人群中 2 型糖尿病患者慢性肾脏病进展的风险预测题目：Randomized-controlled trial of skills-based vr vs. distraction vr vs. sham VR for chronic low back pain 翻译：基于技能的虚拟现实、分散注意力虚拟现实与假虚拟现实治疗慢性下腰痛的随机对照试验题目：Bridging radiology and pathology: domain-generalized cross-modal learning for clinical 翻译：桥接放射学与病理学：面向临床的域泛化跨模态学习 2.肿瘤学 CA-A CANCER JOURNAL FOR CLINICIANS（本周无更新） ANNALS OF ONCOLOGY 题目：Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study 翻译：卡博替尼联合纳武利尤单抗 + 伊匹木单抗治疗初治晚期肾细胞癌：Ⅲ期COSMIC-313 研究最终结果与生物标志物分析题目：Learning the Forest Before the Trees: Artificial Intelligence and Thymic Tumor Pathology 翻译：先见森林后见树木：人工智能与胸腺肿瘤病理学题目：ESMO Adaptation of Lines of Systemic Therapy (EnLiST): a consensus framework for standardising the designation of lines of therapy in solid tumours 翻译：ESMO 系统性治疗线数适配方案（EnLiST）：实体瘤治疗线数定义标准化共识框架题目：Doubting T(h)OMAS: Has the era of precision oncology arrived in uterine leiomyosarcoma? 翻译：质疑 T (h) OMAS：精准肿瘤学时代是否已降临子宫平滑肌肉瘤？题目：PET/CT-Guided Management of Immune Checkpoint Blockade and Post-Treatment Multi-Modal Profiling in Long-Term Responders with Metastatic Lung Cancer in the National Network Genomic Medicine Lung Cancer Germany (nNGM) 翻译：德国国家肺癌基因组医学网络（nNGM）：转移性肺癌长期应答者的PET/CT 指导下免疫检查点阻断治疗管理及治疗后多组学分析 JOURNAL OF CLINICAL ONCOLOGY 题目：Hepatic Arterial Infusion Pump Chemotherapy in Patients With Unresectable Intrahepatic Cholangiocarcinoma—PUMP-2 Trial 翻译：肝动脉灌注泵化疗治疗不可切除肝内胆管癌——PUMP‑2 试验题目：BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 翻译：BRUIN CLL‑313：吡托布鲁替尼对比苯达莫司汀联合利妥昔单抗治疗初治慢性淋巴细胞白血病/ 小淋巴细胞淋巴瘤的随机Ⅲ期试验题目：Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 翻译：吡托布鲁替尼对比伊布替尼治疗初治及复发/ 难治性慢性淋巴细胞白血病/ 小淋巴细胞淋巴瘤题目：Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients With Node-Positive, Hormone Receptor–Positive Breast Cancer: A Cohort Study 翻译：淋巴结阳性、激素受体阳性绝经前乳腺癌患者接受5 年促黄体生成素释放激素激动剂辅助治疗后的延长内分泌治疗：一项队列研究题目：NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal 翻译：NCI9673（B部分）：纳武利尤单抗联合或不联合伊匹木单抗治疗难治性转移性肛管鳞状细胞癌的ETCTN 随机Ⅱ期试验 LANCET ONCOLOGY（本周无更新） JOURNAL OF THORACIC ONCOLOGY（本周无更新） JAMA ONCOLOGY 题目：Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)/SWOG 80702 Phase 3 Randomized Clinical Trial 翻译：循环肿瘤 DNA 在接受塞来昔布治疗的Ⅲ期结肠癌中的预测价值：CALGB（Alliance）/SWOG 80702 Ⅲ期随机临床试验的事后分析题目：Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women: A Secondary Analysis of the RxPONDER Randomized Clinical Trial 翻译：绝经前与绝经后女性的认知功能损伤及化疗内分泌治疗对比内分泌治疗：RxPONDER随机临床试验的二次分析题目：Enhancement of Patient-Centered Lung Cancer Screening: The MyLungHealth Randomized Clinical Trial 翻译：以患者为中心的肺癌筛查优化：MyLungHealth 随机临床试验题目：Quadrivalent Human Papillomavirus Vaccine and High-Grade Vulvovaginal Lesions 翻译：四价人乳头瘤病毒疫苗与高级别外阴阴道病变题目：Baseline Fatigue and Severe Toxic Effects in Patients With Cancer Receiving Systemic Therapy 翻译：接受全身治疗的癌症患者基线疲劳程度与严重毒性反应 CANCER RESEARCH 题目：EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression 翻译：抑制 EZH2 可增加前列腺癌谱系变异演化多样性，但无法有效抑制疾病进展题目：The Aging Microenvironment Is a Determinant of Immune Exclusion and Metastatic Fate in Pancreatic Cancer 翻译：衰老微环境是胰腺癌免疫排斥与转移命运的决定因素题目：Mitochondrial Transfer Rescues Respiration to Support De Novo Pyrimidine Biosynthesis and Tumor Progression 翻译：线粒体转移可恢复呼吸作用，支持从头嘧啶合成与肿瘤进展题目：Dissection of Gαs and Hedgehog Signaling Cross-talk Reveals Therapeutic Opportunities to Target Hedgehog-Dependent Tumors 翻译：解析 Gαs与Hedgehog 信号通路交互作用，为靶向Hedgehog 依赖性肿瘤提供治疗策略题目：Protumor Macrophage Polarization Mediated by BMP2/4–ACVR1 Signaling Orchestrates an Immunosuppressive Microenvironment during Tumor Initiation 翻译：肿瘤发生阶段，BMP2/4–ACVR1信号介导的促肿瘤巨噬细胞极化构建免疫抑制微环境题目：Tetraspanin 13 Enhances Immune Evasion in Breast Cancer by Promoting MHC-I Degradation 翻译：四次跨膜蛋白 13 通过促进MHC‑I 降解增强乳腺癌免疫逃逸题目：Cancer-Associated Fibroblasts Promote Imatinib Resistance in Gastrointestinal Stromal Tumors through PGK1-Mediated Metabolic Reprogramming 翻译：癌相关成纤维细胞通过 PGK1 介导的代谢重编程促进胃肠道间质瘤对伊马替尼耐药题目：Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma 翻译：p300 催化抑制可优先靶向多发性骨髓瘤中IRF4 致癌活性与肿瘤生长题目：CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer 翻译：CRISPR‑Cas9 筛选揭示胰腺癌对KRAS 抑制的耐药机制题目：An Extracellular Matrix–Producing Subset of Cancer-Associated Fibroblasts Drives Chemoresistance in Breast Cancer via SRC Activation and G0S2 Upregulation 翻译：一类分泌细胞外基质的癌相关成纤维细胞亚群通过SRC 激活与G0S2 上调驱动乳腺癌化疗耐药题目：Dynamic and Ongoing De Novo L1 Retrotransposition Contributes to Genome Plasticity and Intrapatient Heterogeneity in Ovarian Cancer 翻译：动态且持续的从头 L1 逆转录转座促进卵巢癌基因组可塑性与患者内异质性 CLINICAL CANCER RESEARCH 题目：Palbociclib, Trastuzumab, and Endocrine Therapy in Pretreated HER2-Positive and PAM50 Luminal Advanced Breast Cancer: Randomized Phase II, SOLTI-1303 PATRICIA Trial 翻译：哌柏西利、曲妥珠单抗联合内分泌治疗既往接受过治疗的HER2 阳性、PAM50腔面型晚期乳腺癌：SOLTI‑1303 PATRICIA 随机Ⅱ期临床试验题目：FDG-PET–Based Selective Deescalation of Chemoradiation in Human Papillomavirus–Related Oropharyngeal Squamous Cell Carcinoma: A Multicenter Phase II Trial 翻译：基于 FDG‑PET 选择性降阶梯放化疗治疗人乳头瘤病毒相关口咽鳞状细胞癌：一项多中心Ⅱ期临床试验题目：T-Cell Receptor and Immune Gene Expression Pharmacodynamics for Durvalumab Alone and with Tremelimumab or Bevacizumab in Unresectable Hepatocellular Carcinoma 翻译：度伐利尤单抗单药或联合曲美木单抗 / 贝伐珠单抗治疗不可切除肝细胞癌的T 细胞受体与免疫基因表达药效学研究题目：HBV Reactivation in Patients with Hepatocellular Carcinoma Treated with PD-1/-L1 Antibodies and Concurrent Antiviral Prophylaxis Agents: A Prospective Observational Study 翻译：PD‑1/PD‑L1 抗体联合预防性抗病毒药物治疗肝细胞癌患者的乙肝病毒再激活：一项前瞻性观察性研究题目：Anti–LAG-3 Antibody LBL-007 plus Tislelizumab and Chemotherapy as First-Line Therapy for Advanced Nasopharyngeal Carcinoma: A Multicenter Phase 2 Trial 翻译：抗 LAG‑3 抗体LBL‑007 联合替雷利珠单抗与化疗作为晚期鼻咽癌一线治疗：一项多中心Ⅱ期临床试验题目：Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma 翻译：GOG281/LOGS 研究的分子谱与肿瘤生物标志物分析：曲美替尼治疗复发性/ 持续性低级别浆液性卵巢癌的阳性晚期试验题目：Investigating Early Kinetics in Plasma ctDNA and Peripheral T-cell Receptor Repertoire to Predict Treatment Outcomes to PD-1 Inhibitors in Head and Neck Squamous Cell Carcinoma 翻译：血浆 ctDNA 早期动力学与外周T 细胞受体库预测头颈部鳞状细胞癌PD‑1 抑制剂治疗疗效题目：Minimal Residual Disease Enhances Prognostic Stratification beyond Pathologic Response in Resectable Non–Small Cell Lung Cancer 翻译：可切除非小细胞肺癌中，微小残留病可在病理缓解之外进一步提升预后分层效能题目：Improving a Plasma Biomarker Panel for Early Detection of Pancreatic Ductal Adenocarcinoma with Aminopeptidase N (ANPEP) and Polymeric Immunoglobulin Receptor (PIGR) 翻译：联合氨基肽酶 N（ANPEP）与多聚免疫球蛋白受体（PIGR）优化胰腺导管腺癌早期检测血浆生物标志物panel 题目：Germline Pathogenic Variant Prediction Model for Tumor-Only Sequencing Based on Japanese Clinicogenomic Database 翻译：基于日本临床基因组数据库的仅肿瘤测序胚系致病变异预测模型题目：Upregulation of TNFR2 Precedes TOX Expression by Exhausted T cells and Restricts Antitumor and Antiviral Immunity 翻译：TNFR2 上调先于耗竭T 细胞TOX 表达，并抑制抗肿瘤与抗病毒免疫题目：Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer 翻译：微卫星不稳定性与肿瘤突变负荷在预测转移性去势抵抗性前列腺癌免疫检查点抑制剂疗效中的附加临床价值题目：A Generative Foundation Model for Scalable Cytology Image Synthesis in AI-Powered Diagnostics 翻译：用于 AI 辅助诊断中可规模化细胞学图像合成的生成式基础模型 JOURNAL OF THE NATIONAL CANCER CENTER 题目：Clinicopathologic, genetic and immune cell infiltration analysis of colorectal signet ring cell carcinoma with comparison to conventional adenocarcinoma 翻译：结直肠印戒细胞癌的临床病理、遗传学及免疫细胞浸润分析——并与常规腺癌对比 JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE（本周无更新） 3.内分泌学与代谢 LANCET DIABETES & ENDOCRINOLOGY 题目：Effect of surgical versus conservative management on cardiovascular outcomes in patients with bilateral adrenal tumours and cortisol excess: an international, retrospective cohort study 翻译：手术治疗对比保守治疗对双侧肾上腺肿瘤合并皮质醇增多患者心血管结局的影响：一项国际回顾性队列研究题目：3 months vs 12 months of romosozumab for postmenopausal osteoporosis (LIDA): an open-label, non-inferiority, randomised controlled trial 翻译：罗莫佐单抗治疗绝经后骨质疏松症 3 个月对比12 个月（LIDA）：一项开放标签、非劣效性随机对照试验题目：Temporal changes and genetic susceptibility to type 2 diabetes (1984–2019; HUNT): a longitudinal, population-based study 翻译：2 型糖尿病的时间变化趋势与遗传易感性（1984–2019；HUNT研究）：一项基于人群的纵向研究题目：Efficacy and safety of inclisiran in adolescents with heterozygous familial hypercholesterolaemia (ORION-16): a two-part, randomised, multicentre clinical trial 翻译：英克西兰治疗杂合子家族性高胆固醇血症青少年的有效性与安全性（ORION‑16）：一项两阶段、多中心随机临床试验 DIABETES CARE 题目：The Effect of Midpregnancy Screening for Gestational Diabetes Mellitus on Pregnancy Outcomes: The TESGO Randomized Controlled Trial 翻译：妊娠中期妊娠期糖尿病筛查对妊娠结局的影响：TESGO随机对照试验题目：Generalizability of Progression Risk in the TN-10 Trial to a European Population With or Without a First-Degree Relative With Type 1 Diabetes 翻译：TN-10 研究中进展风险在有无1 型糖尿病一级亲属的欧洲人群中的外推性题目：Safety and Feasibility of a Fully Automated Insulin Delivery System: FCL@Home, a Multicenter Randomized Clinical Trial in Individuals With Type 1 Diabetes 翻译：全自动胰岛素输注系统的安全性与可行性：FCL@Home——一项针对1 型糖尿病患者的多中心随机临床试验题目：Impact of Maternal Diabetes in Pregnancy on Newborn IgG Antibody Repertoire and Infection Risk in the First 6 Months of Life 翻译：孕期母体糖尿病对新生儿 IgG 抗体谱及出生后6 个月内感染风险的影响题目：MiniMed 780G Advanced Hybrid Closed-Loop System Use During Days Without User-Initiated Boluses 翻译：无用户主动推注期间 MiniMed 780G 高级混合闭环系统的使用情况题目：Metabolic Factors Modulating the Connection Between Diabetes and Pulmonary Alterations 翻译：调控糖尿病与肺部改变之间关联的代谢因素题目：Interoceptive Awareness Moderates the Relationship Between Hypoglycemia Exposure and Symptom Recognition in Adults With Type 1 Diabetes 翻译：内感受感知调节 1 型糖尿病成人低血糖暴露与症状识别之间的关系题目：Associations of Moderate-to-Vigorous Physical Activity Timing With Type 2 Diabetes Incidence in UK Biobank and Prevalent Glycemic Measures in NHANES 翻译：英国生物银行中中高强度体力活动时间与2 型糖尿病发病风险的关联及NHANES 中血糖相关指标的横断面分析题目：Soluble Urokinase Plasminogen Activator Receptor (suPAR) Mediates the Impact of Diabetes on Adverse Outcomes in Coronary Artery Disease 翻译：可溶性尿激酶型纤溶酶原激活物受体（suPAR）介导糖尿病对冠心病不良结局的影响题目：Gout-Related Medication Use After Initiating Sodium–Glucose Cotransporter 2 Inhibitors in Patients With Gout and Type 2 Diabetes: Population-Based Target Trial Emulation Studies 翻译：痛风合并 2 型糖尿病患者启动钠- 葡萄糖协同转运蛋白2 抑制剂后痛风相关药物使用：基于人群的目标试验模拟研究题目：A Comparison of Diet and Exercise During Pregnancy in Women With and Without Type 1 Diabetes Followed in the Environmental Determinants of Islet Autoimmunity (ENDIA) Study 翻译：胰岛自身免疫环境决定因素（ENDIA）研究中1 型糖尿病与非1 型糖尿病孕妇孕期饮食与运动的比较题目：Chronic Kidney Disease and Risk of Diabetic Ketoacidosis in Type 1 Diabetes 翻译：慢性肾脏病与 1 型糖尿病糖尿病酮症酸中毒风险的关系题目：Assessing Time Below Range as a Predictor of Severe Hypoglycemia: Insights From Six Clinical Trials 翻译：评估血糖低于范围时间作为严重低血糖的预测因子：六项临床试验的启示题目：Global, Regional, and National Estimates of Undiagnosed Diabetes in Adults: Findings From the 2025 IDF Diabetes Atlas 翻译：全球、区域及国家层面成人未确诊糖尿病估计：2025年IDF 糖尿病图谱结果题目：Sex Hormones and Cardiovascular Risk in Type 2 Diabetes: Cohort Study of the Look AHEAD Trial 翻译：2 型糖尿病中性激素与心血管风险：Look AHEAD 试验的队列研究题目：Rapid Postpartum Progression to Diabetes Following Early Antenatal Prediabetes: Evidence From a Multiethnic New Zealand Cohort 翻译：孕期早期 prediabetes 后产后快速进展为糖尿病：新西兰多种族队列研究证据 4.心血管病学 CIRCULATION 题目：Hypertensive Disorders of Pregnancy and Premature Cardiovascular Disease in a Diverse Cohort of Young US Women 翻译：妊娠期高血压疾病与美国多种族年轻女性早发性心血管疾病的关系题目：Polycystic Ovarian Syndrome and the Long-Term Risk of Arrhythmias 翻译：多囊卵巢综合征与心律失常长期发病风险题目：Association of Statin Discontinuation in Pregnancy With Maternal Cardiovascular Health and Birth Outcomes: A Nationwide Cohort Study 翻译：孕期停用他汀类药物与母体心血管健康及分娩结局的关联：一项全国性队列研究题目：Breast Cancer Reveals Latent BMPR2-Related Susceptibility to Pulmonary Hypertension 翻译：乳腺癌揭示潜在的BMPR2相关肺动脉高压易感性 EUROPEAN HEART JOURNAL 题目：Catheter ablation in congenital heart diseases: a French nationwide study 翻译：先天性心脏病的导管消融术：一项法国全国性研究题目：Arrhythmias in congenitally corrected transposition of the great arteries: an international study 翻译：先天性矫正型大动脉转位中的心律失常：一项国际研究题目：Early outcomes of children with univentricular circulation undergoing Fontan surgery: the EuroFontan registry 翻译：单心室循环患儿接受 Fontan 手术的早期结局：EuroFontan注册登记研究题目：Adults with Fontan circulation: prognostic value of exercise pulmonary vascular resistance index 翻译：Fontan 循环成人患者：运动肺血管阻力指数的预后价值 JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 题目：Menopausal Status Associated With Docetaxel-Induced Vascular Dysfunction in Breast Cancer Patients 翻译：绝经状态与乳腺癌患者多西他赛诱导的血管功能障碍相关题目：Sex-Specific Microaxial Flow Pump Use and Outcomes in Infarct-Related Cardiogenic Shock in the DanGer Shock Trial 翻译：DanGer 休克研究：梗死相关性心源性休克中微型轴流泵的使用及结局存在性别差异 5.胃肠肝病学 LANCET GASTROENTEROLOGY & HEPATOLOGY（本周无更新） JOURNAL OF HEPATOLOGY 题目：Genetic and non-genetic drivers of histological progression and regression in MASLD 翻译：MASLD 组织学进展与逆转的遗传及非遗传驱动因素题目：HBx-induced HSPB1 is a potential therapeutic target owing to its modulation of HBV cccDNA and hepatic immune responses 翻译：HBx 诱导的HSPB1 通过调控HBV cccDNA 与肝脏免疫反应成为潜在治疗靶点题目：Safety and efficacy of REP 2139-Mg in patients with HDV-related advanced liver disease in an international compassionate access program 翻译：国际同情用药项目中 REP 2139-Mg 治疗HDV 相关晚期肝病的安全性与有效性题目：Refining the Baveno VII criteria for clinically significant portal hypertension: An individual patient data meta-analysis 翻译：优化具有临床意义门静脉高压的 Baveno VII 标准：一项个体患者数据荟萃分析题目：Setd4-expressing cells drive regenerative recovery in chronic liver injury 翻译：表达 Setd4 的细胞介导慢性肝损伤的再生修复题目：Strategies to address non-proportional hazards between survival curves - Lessons from phase III trials in hepatocellular carcinoma 翻译：处理生存曲线间非比例风险的策略——来自肝细胞癌Ⅲ期试验的启示题目：HES V2.0 validation and performance compared to GALAD and ASAP in the HEDS cohort 翻译：HEDS 队列中HES V2.0 与GALAD、ASAP的对比验证及性能评估题目：Genetically engineered pig-to-human liver xenotransplantation 翻译：基因工程猪 - 人肝脏异种移植题目：PARG inhibition halts cholangiocarcinoma progression via the Hippo pathway and enhances response to chemotherapy and immunotherapy 翻译：PARG 抑制通过Hippo 通路阻断胆管癌进展并增强化疗与免疫治疗应答题目：Transcriptomic and epigenetic mechanisms controlling cholangiocyte transdifferentiation into hepatocytes 翻译：调控胆管细胞转分化为肝细胞的转录组与表观遗传机制 GUT 题目：MTFP1 drives pancreatic cancer liver metastatic colonisation by regulating mitochondrial metabolism reprogramming 翻译：MTFP1 通过调控线粒体代谢重编程驱动胰腺癌肝转移定植题目：Oleic acid promotes lung injury in hypertriglyceridaemia-associated acute pancreatitis via the PIEZO1/NR4A1/CPT1A axis impairing endothelial fatty acid oxidation 翻译：油酸通过 PIEZO1/NR4A1/CPT1A 轴损伤内皮细胞脂肪酸氧化，加重高甘油三酯血症相关性急性胰腺炎的肺损伤题目：E-cadherin loss in Cd44-positive gastric cells initiates diffuse gastric cancer in a murine model 翻译：小鼠模型中 Cd44 阳性胃上皮细胞E‑钙黏蛋白缺失可启动弥漫型胃癌发生题目：Spatial profiling of patient-matched HER2 positive gastric cancer reveals resistance mechanisms to targeted therapy 翻译：患者配对 HER2 阳性胃癌的空间组学分析揭示靶向治疗耐药机制 GASTROENTEROLOGY 题目：Gastric Organoid-Based Ectopic and Orthotopic In Vivo CRISPR Screening for Tumor Suppressors in Gastric Cancer 翻译：基于胃类器官的异位及原位体内 CRISPR 筛选胃癌肿瘤抑制基因题目：Postoperative Ileum Transcriptomics Implicate Sex-Biased Mechanisms in Crohn’s Disease Recurrence 翻译：术后回肠转录组学提示克罗恩病复发中存在性别差异机制题目：Fecal Detection of Calprotectin Subunits Links Inflammatory Bowel Disease Activity With Chronicity of Intestinal Inflammation 翻译：粪便钙卫蛋白亚基检测将炎症性肠病活动度与肠道炎症慢性化相关联题目：The Gut Microbiome at the Onset of Inflammatory Bowel Disease: A Systematic Review and Unified Bioinformatic Synthesis 翻译：炎症性肠病发病时的肠道微生物组：一项系统评价与统一生物信息学整合分析题目：Mutational Landscape of Colorectal Tumors From Individuals With Unexplained Adenomatous or Serrated Colorectal Polyposis 翻译：原因不明腺瘤性或锯齿状结肠息肉病患者结直肠肿瘤的突变图谱题目：Clusterin Drives Fiber Endocytosis by Mesothelial Cells to Resolve Liver Fibrosis 翻译：簇蛋白驱动间皮细胞摄取纤维以缓解肝纤维化题目：Endoscopic Ultrasound-Guided Choledochoduodenostomy vs Endoscopic Retrograde Cholangiopancreatography in Malignant Distal Biliary Obstruction to Prevent Postprocedural Pancreatitis: A Randomized Trial 翻译：内镜超声引导下胆管十二指肠吻合术 vs 内镜逆行胰胆管造影用于恶性远端胆道梗阻以预防术后胰腺炎：一项随机试验题目：Utility of Serum Biomarkers in Addition to Ultrasound for Early Detection of Hepatocellular Carcinoma in High-Risk Patients: A Randomized Controlled Trial 翻译：高危患者中血清生物标志物联合超声用于肝细胞癌早期检测的价值：一项随机对照试验题目：Changes in Liver Disease Etiology Support a Lower Alpha-Fetoprotein Threshold for Hepatocellular Carcinoma Screening 翻译：肝病病因变化支持降低甲胎蛋白阈值用于肝细胞癌筛查 6.呼吸病学 LANCET RESPIRATORY MEDICINE（本周无更新） EUROPEAN RESPIRATORY JOURNAL（本周无更新） 7.感染与微生物 LANCET INFECTIOUS DISEASES（本周无更新） LANCET MICROBE（本周无更新） NATURE MICROBIOLOGY 题目：Gut microbial ammonia enhances colonic acetylcholine levels to regulate intestinal motility 翻译：肠道微生物产生的氨升高结肠乙酰胆碱水平并调节肠道动力题目：Conserved CD4+ T cell staphylococcal and streptococcal epitopes enable broad-acting vaccines in mice 翻译：保守的 CD4⁺T 细胞葡萄球菌与链球菌表位可在小鼠中实现广谱疫苗作用题目：Longitudinal plasma metabolomics reveals a role for taurine in asymptomatic malaria and seasonal persistence 翻译：纵向血浆代谢组学揭示牛磺酸在无症状疟疾与季节性持续感染中的作用题目：Candida aurisvacuolar calcium pump mediates fluconazole efflux and resistance evolution 翻译：耳念珠菌液泡钙泵介导氟康唑外排与耐药进化题目：Human immunodeficiency virus-associated gut microbiome impacts systemic immunodeficiency and susceptibility to opportunistic gut infection 翻译：人类免疫缺陷病毒相关肠道微生物组影响全身性免疫缺陷及机会性肠道感染易感性 MICROBIOME 题目：Comparative analysis of rumen metagenomes with dietary supplementation of 3-nitrooxypropanol revealed divergent modes of action in hydrogen metabolism and reductant pathways between beef and dairy cattle 翻译：日粮添加 3‑硝基氧丙醇的瘤胃宏基因组比较分析揭示肉牛与奶牛在氢代谢及还原通路中存在不同作用模式题目：Microbiota-derived propionate suppresses Salmonella virulence gene expression via LuxS quorum sensing 翻译：微生物组来源的丙酸通过 LuxS 群体感应抑制沙门菌毒力基因表达题目：Association between the gut microbiome and plasma metabolites linked to vocalization-based temperament in Merino sheep 翻译：美利奴绵羊肠道微生物组与血浆代谢物的关联和基于发声的气质相关题目：Cross-kingdom genomic variation in chicken gut microbiomes: insights from China’s diverse local breeds 翻译：鸡肠道微生物组的跨界基因组变异：来自中国多样地方品种的启示 JOURNAL OF INFECTION（本周无更新） 8.公共卫生和流行病学 LANCET PUBLIC HEALTH（本周无更新） LANCET GLOBAL HEALTH 题目：Global estimates of tuberculosis incidence during pregnancy and postpartum: a rapid review and modelling analysis 翻译：全球孕期及产后期结核病发病率估计：一项快速综述与模型分析题目：Characterising progression and regression patterns across the spectrum of tuberculosis: a multistate modelling approach 翻译：结核病全疾病谱进展与转归模式特征：多状态模型研究题目：Avoidable deaths through the primary prevention, early detection, and curative treatment of cancer worldwide: a population-based study 翻译：全球通过癌症一级预防、早期筛查与根治性治疗可避免的死亡：一项基于人群的研究题目：Effective cataract surgical coverage in adults aged 50 years and older: empirical estimates from population-based surveys in 68 countries and modelled estimates for 2000–30 翻译：50 岁及以上成人有效白内障手术覆盖率：来自68 国人群调查的实证估计及2000–2030年模型预测题目：Early assessment of maternal bleeding: development and validation of a prognostic model predicting death and near miss 翻译：孕产妇出血早期评估：预测死亡与危重不良事件预后模型的建立与验证题目：Low-dose aspirin for preventing intrauterine growth restriction and pre-eclampsia in sickle cell pregnancy in Nigeria (PIPSICKLE): a randomised controlled trial 翻译：尼日利亚镰状细胞病孕妇使用小剂量阿司匹林预防胎儿生长受限与子痫前期（PIPSICKLE）：一项随机对照试验题目：Evaluation of fluorometholone as adjunctive medical therapy for trachomatous trichiasis surgery (FLAME): a parallel, double-blind, randomised controlled field trial in the Jimma Zone, Ethiopia 翻译：氟米龙作为沙眼性倒睫手术辅助药物治疗的评估（FLAME）：埃塞俄比亚吉马地区平行、双盲、随机对照现场试验题目：Effectiveness of behavioural tobacco cessation interventions with and without pharmacotherapy among people living with HIV in Viet Nam: a three-arm pragmatic randomised controlled trial 翻译：越南 HIV 感染者中联合或不联合药物治疗的行为戒烟干预效果：三臂实用性随机对照试验题目：Prevalence and outcomes of intrinsic capacity impairments assessed using the WHO Integrated Care for Older People (ICOPE) framework in The Gambia, South Africa, and Zimbabwe: a cross-sectional study 翻译：采用 WHO 老年人综合照护（ICOPE）框架评估冈比亚、南非与津巴布韦内在能力受损的患病率与结局：一项横断面研究题目：Measuring the impact of global research and development investment in product development partnerships: a case study on return on investment in antimalarial drug development 翻译：评估全球研发投入对产品开发伙伴关系的影响：抗疟药物研发投资回报案例分析题目：Cost and cost-effectiveness of ivermectin mass drug administration for malaria control in Kwale county, Kenya: a modelling analysis of a cluster-randomised trial 翻译：肯尼亚夸勒县伊维菌素大规模给药用于疟疾防控的成本及成本效果：整群随机试验模型分析 9.内科学 JAMA INTERNAL MEDICINE（本周无更新） ANNALS OF INTERNAL MEDICINE 题目：Effectiveness and Safety of Statins in Type 2 Diabetes According to Baseline Cardiovascular Risk 翻译：根据基线心血管风险分层分析他汀类药物在2 型糖尿病中的有效性与安全性题目：Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1 翻译：每周一次口服伊司拉韦 + 来那卡帕韦对比每日口服比克替拉韦/ 恩曲他滨/ 丙酚替诺福韦治疗HIV‑1 感染者题目：Integrating Methadone Services Into Primary Care in Ukraine: Two-Year Outcomes From a Randomized Trial 翻译：将美沙酮服务整合至乌克兰初级保健：一项随机试验的2 年结局题目：Diagnostic Follow-up of Positive Results on Low-Dose Computed Tomography Screening in the Medicare Population 翻译：美国医保人群低剂量 CT 筛查阳性结果后的诊断随访题目：Eligibility and Prognostic Performance of Smoking Duration–Based Versus Pack-Year–Based U.S. National Lung Cancer Screening Criteria Across Racial and Ethnic Groups 翻译：美国国家肺癌筛查标准中：基于吸烟年限vs 基于包年的适用人群与预后表现在不同种族/ 族裔间的对比题目：The Incubation Periods of Mpox Virus Clade Ib 翻译：猴痘病毒 Ib 分支的潜伏期 10.血液学 LANCET HAEMATOLOGY（本周无更新） 11.牙科与口腔外科 JOURNAL OF CLINICAL PERIODONTOLOGY（本周无更新）

2026-02-21

·中金财富证券

美股内部交易 | 伊克力西斯于2月20日披露2笔公司内部人交易情况

2026年2月20日，伊克力西斯（EXEL）披露2笔公司内部人交易情况。董事WYSZOMIERSKI JACK L于2026年2月18日卖出9.96万股。【近期内部交易】披露日期职位姓名交易日期买/卖数量每股成交价/美元总金额/美元2026年2月20日董事WYSZOMIERSKI JACK L2026年2月18日卖出9.96万44.01438.23万2026年2月20日董事WYSZOMIERSKI JACK L2026年2月18日买入2.06万19.7740.79万2026年2月19日董事Smith Julie2026年2月18日卖出4.41万44.50196.19万2026年2月19日董事Smith Julie2026年2月17日卖出4.24万43.33183.81万2026年2月19日董事Smith Julie2026年2月18日买入2.00万21.6943.45万2026年2月19日董事Smith Julie2026年2月18日卖出2.00万44.3088.73万2026年2月19日董事Smith Julie2026年2月17日买入4.24万18.1977.17万2026年2月19日董事Smith Julie2026年2月18日买入4.41万19.3985.48万2026年2月18日高管Senner Christopher J.2026年2月13日卖出3.43万43.00147.40万2026年2月18日董事MORRISSEY MICHAEL2026年2月15日卖出49.00万43.922152.06万【公司资料】Exelixis, Inc.是一家生物科技公司，致力于研发癌症小分子治疗。公司于1994年11月在特拉华州注册为Exelixis制药股份有限公司，并于2000年2月改为Exelixis股份有限公司。该公司已推出四款上市药品，其中包括其旗舰分子卡博替尼的两种制剂。Exelixis 正在积极推进其产品线，其主要临床候选药物赞扎替尼目前正在接受美国食品药品监督管理局 (FDA) 的审查，用于治疗特定类型的结直肠癌 (CRC)。该公司还拥有一个庞大的后期临床开发项目，旨在开发其他适应症。凭借理性严谨的投资策略，Exelixis 利用其内部专业知识和强大的战略合作伙伴关系，在包括小分子药物和生物疗法（例如抗体药物偶联物 (ADC)）在内的各种科学领域中寻找并把握机遇。

财报抗体药物偶联物

100 项与苹果酸卡博替尼相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10095	苹果酸卡博替尼	L01XE26	DB08875

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
神经内分泌肿瘤	英国	Ipsen SA	2025-09-26
高分化胰腺内分泌肿瘤	欧盟	Ipsen Pharma SAS	2025-07-24
高分化胰腺内分泌肿瘤	冰岛	Ipsen Pharma SAS	2025-07-24
高分化胰腺内分泌肿瘤	列支敦士登	Ipsen Pharma SAS	2025-07-24
高分化胰腺内分泌肿瘤	挪威	Ipsen Pharma SAS	2025-07-24
胰腺外神经内分泌肿瘤	澳大利亚	Ipsen Pty Ltd.	2018-01-19
胰腺神经内分泌肿瘤	澳大利亚	Ipsen Pty Ltd.	2018-01-19
分化型甲状腺癌	韩国	Ipsen Ltd.	2017-09-26
肾细胞癌	韩国	Ipsen Ltd.	2017-09-26
肝细胞癌	欧盟	Ipsen Pharma SAS	2016-09-09
肝细胞癌	冰岛	Ipsen Pharma SAS	2016-09-09
肝细胞癌	列支敦士登	Ipsen Pharma SAS	2016-09-09
肝细胞癌	挪威	Ipsen Pharma SAS	2016-09-09
晚期肾细胞癌	美国	Exelixis, Inc.	2016-04-25
甲状腺髓样癌	美国	Exelixis, Inc.	2012-11-29

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
实体瘤	申请上市	中国	江苏豪森药业集团有限公司	2020-09-28
难治性分化型甲状腺癌	临床3期	美国	ECOG-ACRIN Medical Research Foundation, Inc.	2024-08-22
难治性甲状腺癌	临床3期	美国	ECOG-ACRIN Medical Research Foundation, Inc.	2024-08-22
转移性骨肉瘤	临床3期	美国	National Cancer Institute	2023-03-03
转移性骨肉瘤	临床3期	澳大利亚	National Cancer Institute	2023-03-03
转移性骨肉瘤	临床3期	加拿大	National Cancer Institute	2023-03-03
转移性骨肉瘤	临床3期	新西兰	National Cancer Institute	2023-03-03
晚期尿路上皮癌	临床3期	美国	National Cancer Institute	2022-06-03
晚期尿路上皮癌	临床3期	加拿大	National Cancer Institute	2022-06-03
膀胱癌	临床3期	美国	National Cancer Institute	2022-06-03

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04200443 (Pubmed \| Lancet Oncol)	临床2期	平滑肌肉瘤 \| 软组织肉瘤	72	Cabozantinib 40 mgTemozolomide 40 mg + Cabozantinib 40 mgTemozolomide	願願繭簾觸廠築糧鑰構(鏇淵鏇膚獵憲蓋醖顧衊) = 齋築壓鏇壓積簾夢淵製壓壓憲觸蓋範壓獵繭構 (艱夢憲廠艱鬱鏇簾餘顧 ) 更多	积极	2026-02-01
				Temozolomide (Cohort 1)	鹽齋廠鹹鑰願艱築築築(鹹齋觸壓範淵蓋獵顧鹹) = 觸製築憲夢窪繭鏇網網顧膚衊顧範夢壓醖遞獵 (淵觸繭鹽積積夢窪鬱餘 ) 更多
NCT00596648 (CTgov)	临床1/2期	非小细胞肺癌	92	erlotinib+cabozantinib (Phase 1 - Cohort 1)	獵範獵醖鑰鬱糧鬱廠廠(鏇蓋鑰選網艱鹽膚構選) = 製觸積鹽淵網範選齋夢窪餘蓋淵鹹製築醖衊製 (鏇餘艱構顧膚範衊製鏇, 遞壓醖願襯夢築築淵鑰 ~ 鹽鹽獵襯遞壓夢壓壓選) 更多	-	2026-01-13
				erlotinib+cabozantinib (Phase 1 - Cohort 2A)	獵範獵醖鑰鬱糧鬱廠廠(鏇蓋鑰選網艱鹽膚構選) = 築遞繭鬱鹽鏇膚餘蓋網窪餘蓋淵鹹製築醖衊製 (鏇餘艱構顧膚範衊製鏇, 構遞構襯簾遞廠齋網積 ~ 網齋網觸糧鏇獵簾夢網) 更多
NCT03375320 (CABINET, Pubmed \| Endocr Relat Cancer)	临床3期	神经内分泌肿瘤	96	Cabozantinib-Malate	觸糧夢製選壓鹽製壓鹽(積構構選遞窪襯齋壓簾) = 膚鬱獵鏇齋蓋餘遞蓋範醖網鹹選簾願餘鑰壓繭 (製獵鏇鏇構襯製鑰淵簾 )	积极	2026-01-12
				Placebo	觸糧夢製選壓鹽製壓鹽(積構構選遞窪襯齋壓簾) = 鬱窪製構獵蓋獵網壓窪醖網鹹選簾願餘鑰壓繭 (製獵鏇鏇構襯製鑰淵簾 )
NCT01995058 (CTgov)	临床2期	转移性去势抵抗性前列腺癌	54	prednisone+abiraterone+Cabozantinib (Arm 1)	淵膚淵廠鑰繭淵夢淵醖(顧選壓衊襯繭艱遞範鹽) = 顧鹽膚製膚衊鑰構製遞遞糧膚夢鬱獵廠壓醖廠 (獵糧蓋鬱選夢積壓觸淵, 鏇淵鹹簾遞願鬱窪築製 ~ 構顧衊膚廠鏇繭獵淵網) 更多	-	2026-01-08
				prednisone+abiraterone+Cabozantinib (Arm 2)	淵膚淵廠鑰繭淵夢淵醖(顧選壓衊襯繭艱遞範鹽) = 願衊餘顧願製醖壓廠襯遞糧膚夢鬱獵廠壓醖廠 (獵糧蓋鬱選夢積壓觸淵, 餘願醖蓋糧膚餘選壓膚 ~ 獵窪遞鏇築襯艱觸窪顧) 更多
NCT03141177 (CheckMate 9ER, Pubmed \| J Immunother Cancer)	临床3期	晚期肾细胞癌一线	651	Nivolumab+Cabozantinib	襯艱觸網鹽鹹齋鹽鬱築(簾積夢襯膚蓋選襯鑰膚) = 壓襯淵淵餘壓獵積獵膚願觸窪網襯鬱範鏇顧壓 (製觸願繭願齋憲餘繭鹽 ) 更多	积极	2026-01-01
				Sunitinib	襯艱觸網鹽鹹齋鹽鬱築(簾積夢襯膚蓋選襯鑰膚) = 網壓觸鬱膚鬱糧膚繭願願觸窪網襯鬱範鏇顧壓 (製觸願繭願齋憲餘繭鹽 ) 更多
NCT04446117 (CONTACT-02 \| CONTACT-2, CTgov)	临床3期	转移性去势抵抗性前列腺癌 \| 前列腺腺癌	575	Cabozantinib+Atezolizumab (Experimental Arm: Cabozantinib and Atezolizumab)	鏇廠構簾壓廠構鏇鑰齋(製夢網夢積簾壓遞積憲) = 窪壓築構鏇觸艱壓餘艱鬱選夢艱選壓顧廠顧鏇 (鬱選壓遞願網憲觸蓋範, 獵壓遞鏇夢淵憲製鬱鹽 ~ 鹹齋廠壓願餘鬱蓋獵繭) 更多	-	2025-12-18
				enzalutamide+prednisone+abiraterone (Control Arm: Second NHT)	鏇廠構簾壓廠構鏇鑰齋(製夢網夢積簾壓遞積憲) = 顧淵鑰醖構醖夢簾衊艱鬱選夢艱選壓顧廠顧鏇 (鬱選壓遞願網憲觸蓋範, 壓鹹壓醖網鹽鹽遞艱壓 ~ 簾構壓築蓋鬱糧廠簾衊) 更多
NCT04079712 (CTgov)	临床2期	大细胞神经内分泌癌 \| 小细胞癌 \| 胰岛细胞癌 ... 更多	17	Ipilimumab+Nivolumab+Cabozantinib S-malate	鬱觸膚觸廠鹹蓋築衊壓(憲餘衊淵築願顧簾廠醖) = 網積鏇願鏇艱鏇夢夢廠憲壓積壓鑰願簾膚鹹醖 (簾艱淵憲簾顧築憲顧鏇, 構壓鏇膚衊艱窪構艱顧 ~ 鏇觸窪獵窪構願廠觸築) 更多	-	2025-12-12
NCT03755791 (COSMIC-312, CTgov)	临床3期	晚期肝细胞癌	837	Cabozantinib+Atezolizumab (Experimental Arm: Cabozantinib + Atezolizumab)	醖襯願構顧艱獵築選築(艱鏇夢壓淵鏇遞窪齋蓋) = 齋網廠壓醖餘繭廠糧淵窪鏇艱積製膚鹹艱廠範 (積製鏇鏇壓鏇衊網觸網, 鹹願願製築淵衊鏇遞遞 ~ 壓遞鑰齋鑰觸繭蓋簾選) 更多	-	2025-12-11
				Sorafenib (Control Arm: Sorafenib)	醖襯願構顧艱獵築選築(艱鏇夢壓淵鏇遞窪齋蓋) = 夢衊選憲衊餘範願觸餘窪鏇艱積製膚鹹艱廠範 (積製鏇鏇壓鏇衊網觸網, 觸糧衊構淵積選膚構襯 ~ 顧鑰齋淵繭艱糧憲醖膚) 更多
NCT05052723 (CTgov)	临床2期	转移性胰腺癌	21	Cabozantinib+Pembrolizumab	蓋鹹醖鹽齋醖醖襯製鬱 = 繭製蓋觸繭顧網齋壓憲鹹鏇襯獵願鹹鏇製積鑰 (簾蓋鑰淵襯壓觸淵餘築, 網醖網衊獵蓋淵憲蓋窪 ~ 願鬱網觸範構糧繭鬱顧) 更多	-	2025-11-19
NCT03141177 (CheckMate 9ER, Pubmed \| Oncol Ther)	临床3期	晚期肾细胞癌一线	540	Cabozantinib plus nivolumab (CaboNivo)	構鹹襯簾獵願壓繭願衊(艱願觸廠鹽淵範製艱範) = 夢築簾簾膚蓋築齋構淵鑰獵壓範鬱選簾壓獵齋 (範糧醖選願範築網憲餘, 40.6 ~ 53.7) 更多	优效	2025-11-15
				sunitinib (SUN)	構鹹襯簾獵願壓繭願衊(艱願觸廠鹽淵範製艱範) = 積壓蓋網蓋衊鹹淵淵簾鑰獵壓範鬱選簾壓獵齋 (範糧醖選願範築網憲餘, 29.2 ~ 42.8) 更多